Dyskinesias in Parkinson's disease: views from positron emission tomography studies

Levodopa‐induced dyskinesias (LIDs) and graft‐induced dyskinesias (GIDs) are serious and common complications of Parkinson's disease (PD) management following chronic treatment with levodopa or intrastriatal transplantation with dopamine‐rich foetal ventral mesencephalic tissue, respectively. Positron emission tomography (PET) molecular imaging provides a powerful in vivo tool that has been employed over the past 20 years for the elucidation of mechanisms underlying the development of LIDs and GIDs in PD patients. PET used together with radioligands tagging molecular targets has allowed the functional investigation of several systems in the brain including the dopaminergic, serotonergic, glutamatergic, opioid, endocannabinoid, noradrenergic and cholinergic systems. In this article the role of PET imaging in unveiling pathophysiological mechanisms underlying the development of LIDs and GIDs in PD patients is reviewed.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  J. Costentin,et al.  Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats , 2012, Experimental Neurology.

[3]  M. Politis,et al.  Buspirone: What is it all about? , 2012, Brain Research.

[4]  A. Björklund,et al.  Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson’s Patients Treated with Dopamine Grafts , 2012, Science Translational Medicine.

[5]  Igor D. Grachev,et al.  Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo , 2012, Neurobiology of Aging.

[6]  A. Martinez,et al.  The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats , 2012, Neuroscience Research.

[7]  Marios Politis,et al.  Positron emission tomography imaging in neurological disorders , 2012, Journal of Neurology.

[8]  C. Barnum,et al.  Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats , 2012, Pharmacology Biochemistry and Behavior.

[9]  A. Benazzouz,et al.  Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism , 2012, Neuroscience.

[10]  Zhi-Yong Wang,et al.  Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease , 2011, Brain Research.

[11]  D. Brooks,et al.  Serotonergic mediated body mass index changes in Parkinson's disease , 2011, Neurobiology of Disease.

[12]  O. Lindvall,et al.  Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  Marios Politis,et al.  Positron emission tomography neuroimaging in Parkinson's disease. , 2011, American journal of translational research.

[14]  C. Barnum,et al.  Behavioral and Cellular Modulation of l-DOPA-Induced Dyskinesia by β-Adrenoceptor Blockade in the 6-Hydroxydopamine-Lesioned Rat , 2011, Journal of Pharmacology and Experimental Therapeutics.

[15]  F. Turkheimer,et al.  Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.

[16]  M. Politis.  Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease , 2011, BMC medicine.

[17]  Alexander Hammers,et al.  Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.

[18]  S. Kitamura,et al.  Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.

[19]  S. A. O. Lim,et al.  Enhanced striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian mice , 2010, Proceedings of the National Academy of Sciences.

[20]  F. Turkheimer,et al.  Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures , 2010, Neurology.

[21]  D. Brooks,et al.  Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study , 2010, Neurobiology of Disease.

[22]  Marios Politis,et al.  Parkinson's disease symptoms: The patient's perspective , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  Y. Mizuno,et al.  Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[24]  O. Lindvall,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[25]  K. Mackie,et al.  Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat , 2010, Brain Research Bulletin.

[26]  K. Buck,et al.  The selective α1 adrenoceptor antagonist HEAT reduces L‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease , 2010, Synapse.

[27]  Jeih-San Liow,et al.  Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand , 2009, NeuroImage.

[28]  A. Björklund,et al.  Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.

[29]  L. Grégoire,et al.  Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. , 2009, Parkinsonism & related disorders.

[30]  Philippe Hantraye,et al.  Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  T. Deak,et al.  Contribution of the striatum to the effects of 5‐HT1A receptor stimulation in L‐DOPA‐treated hemiparkinsonian rats , 2009, Journal of neuroscience research.

[32]  A. Stoessl,et al.  PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.

[33]  J. Gracies,et al.  Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis , 2009, Movement disorders : official journal of the Movement Disorder Society.

[34]  A. Björklund,et al.  Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. , 2008, Brain : a journal of neurology.

[35]  Hidehiko Takahashi,et al.  Quantitative Analysis of Norepinephrine Transporter in the Human Brain Using PET with (S,S)-18F-FMeNER-D2 , 2008, Journal of Nuclear Medicine.

[36]  R. Albin,et al.  Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  D. D. Di Monte,et al.  Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys , 2007, Annals of neurology.

[38]  T. Cassano,et al.  Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors , 2007, Experimental Neurology.

[39]  Junchao Tong,et al.  Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. , 2007, Brain : a journal of neurology.

[40]  Vikas Gupta,et al.  The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy , 2007, Pharmacology Biochemistry and Behavior.

[41]  N. Volkow,et al.  Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. , 2007, Nuclear medicine and biology.

[42]  B. Gulyás,et al.  Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2 , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  Alan A. Wilson,et al.  Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease , 2007, European journal of neurology.

[44]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[45]  Erwan Bezard,et al.  Enhanced Preproenkephalin-B–Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanine–Induced Dyskinesia , 2007, Biological Psychiatry.

[46]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[47]  J. Brotchie,et al.  Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia , 2007, Movement disorders : official journal of the Movement Disorder Society.

[48]  Yen F. Tai,et al.  Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.

[49]  J. Langston,et al.  Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates , 2006, The Journal of Neuroscience.

[50]  A. Björklund,et al.  Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia , 2006, Neurobiology of Disease.

[51]  P. Spano,et al.  Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat , 2006, Molecular Pharmacology.

[52]  T. Chase,et al.  Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD , 2005, Experimental Neurology.

[53]  A. Björklund,et al.  Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. , 2005, Brain : a journal of neurology.

[54]  C. Halldin,et al.  Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2 , 2005, European Neuropsychopharmacology.

[55]  J. Brotchie,et al.  A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  K. Nagata,et al.  Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA , 2005, Brain Research.

[57]  G. Bernardi,et al.  High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients , 2005, Annals of neurology.

[58]  J. Mcsherry.  Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study , 2005, Neurology.

[59]  E. Bézard,et al.  Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.

[60]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[61]  L Teare,et al.  Cannabis for dyskinesia in Parkinson disease , 2004, Neurology.

[62]  E. Růžička,et al.  Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms , 2004, Movement disorders : official journal of the Movement Disorder Society.

[63]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[64]  R. P. Maguire,et al.  Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications , 2004, Journal of Neural Transmission.

[65]  D. Mash,et al.  Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain , 2003, Journal of Neural Transmission.

[66]  D. Piomelli,et al.  Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias , 2003, The European journal of neuroscience.

[67]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[68]  C. Tanner.  PD or not PD? , 2003, Neurology.

[69]  P. Calabresi,et al.  Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism , 2003, Journal of neurochemistry.

[70]  Nicola Pavese,et al.  Endogenous dopamine release after pharmacological challenges in Parkinson's disease , 2003, Annals of neurology.

[71]  C. Clarke,et al.  Amantadine for dyskinesia in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.

[72]  F. Mora,et al.  Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[73]  J. Brotchie.  CB1 cannabinoid receptor signalling in Parkinson's disease. , 2003, Current opinion in pharmacology.

[74]  Stanley Fahn,et al.  Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.

[75]  J. Brotchie,et al.  Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[76]  S. L. Nicholson,et al.  5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. , 2002, European journal of neurology.

[77]  P. Calabresi,et al.  Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission , 2002, The Journal of Neuroscience.

[78]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[79]  J. Brotchie,et al.  Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat , 2002, Movement disorders : official journal of the Movement Disorder Society.

[80]  P. Blanchet,et al.  Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[81]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[82]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[83]  P. Jenner,et al.  Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets , 2001, The European journal of neuroscience.

[84]  T. Chase,et al.  Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models , 2001, Neurology.

[85]  V. Sossi,et al.  Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[86]  R. E. Adams,et al.  Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage , 2001, Neurology.

[87]  M. Andersson,et al.  Alterations in Cortical and Basal Ganglia Levels of Opioid Receptor Binding in a Rat Model of l -DOPA-Induced Dyskinesia , 2001, Neurobiology of Disease.

[88]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[89]  M. Matsunaga,et al.  Activation of 5‐HT1A but not 5‐HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l‐DOPA in the striatum with nigrostriatal denervation , 2001, Journal of neurochemistry.

[90]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[91]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[92]  C. Marsden,et al.  Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.

[93]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  J. Rinne,et al.  Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.

[95]  J. Penney,et al.  Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum , 2000, The Journal of comparative neurology.

[96]  P. Jenner,et al.  Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA , 2000, The European journal of neuroscience.

[97]  T. Suda,et al.  Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.

[98]  D J Brooks,et al.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.

[99]  W C Eckelman,et al.  Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[100]  D. J. Brooks,et al.  In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias , 1997, Neurology.

[101]  Björn Gustavii,et al.  Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.

[102]  S. DeKosky,et al.  Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. , 1997, Cell transplantation.

[103]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[104]  E. Richelson,et al.  The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain. , 1997, Brain research. Molecular brain research.

[105]  A. Levey,et al.  Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease , 1996, Neurology.

[106]  B. Långström,et al.  Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET , 1996, Neurology.

[107]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[108]  C. Freed,et al.  Transplantation of fetal mesencephalic tissue in Parkinson's disease. , 1995, The New England journal of medicine.

[109]  C. Marsden,et al.  L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. , 1995, Brain research. Molecular brain research.

[110]  R. Arai,et al.  l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study , 1995, Neuroscience Letters.

[111]  R. Arai,et al.  Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase , 1994, Brain Research.

[112]  Y. Samson,et al.  Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. , 1994, Brain : a journal of neurology.

[113]  P. Bédard,et al.  Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.

[114]  M. Giroud,et al.  Cerebrospinal fluid choline levels in Parkinson's disease , 1993, Annals of neurology.

[115]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[116]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[117]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.

[118]  R. Hichwa,et al.  In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography , 1992 .

[119]  G. Bravo,et al.  Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease. Clinica Puerta de Hierro Neural Transplantation Group. , 1991, Journal of neurosurgery.

[120]  C. Clough,et al.  Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. , 1991, Archives of neurology.

[121]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[122]  Richard S. J. Frackowiak,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[123]  Scott T. Grafton,et al.  Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.

[124]  R. Franco-Bourland,et al.  [Human fetal homograft to the nigrostriatal system for the treatment of Parkinson's disease]. , 1990, Archivos de investigacion medica.

[125]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[126]  B J Hoffer,et al.  Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.

[127]  Alan J. Cross,et al.  Subtraction autoradiography of opiate receptor subtypes in human brain , 1987, Brain Research.

[128]  D L Price,et al.  Aminergic systems in Alzheimer's disease and Parkinson's disease , 1987, Annals of neurology.

[129]  Yves Agid,et al.  A subcortico-cortical cholinergic system is affected in Parkinson's disease , 1983, Brain Research.

[130]  Y. Agid,et al.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.

[131]  C. Marsden.  BASAL GANGLIA DISEASE , 1982, The Lancet.

[132]  A. Björklund,et al.  Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing , 1980, Brain Research.

[133]  A. Lees,et al.  "OFF PERIOD" DYSTONIA AND "ON PERIOD" CHOREOATHETOSIS IN LEVODOPA-TREATED PATIENTS WITH PARKINSON'S DISEASE , 1977, The Lancet.

[134]  D. Jenden,et al.  Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea. , 1976, Journal of neurology, neurosurgery, and psychiatry.

[135]  M. Seller.  SCREENING FOR NEURAL-TUBE DEFECTS , 1975, The Lancet.

[136]  I. Kopin,et al.  Effects of L-Dopa on Efflux of Cerebral Monoamines from Synaptosomes , 1971, Nature.

[137]  T. Chase,et al.  L-Dopa-Induced Release of Cerebral Monoamines , 1970, Science.

[138]  P. Piccini,et al.  In vivo imaging of the integration and function of nigral grafts in clinical trials. , 2012, Progress in brain research.

[139]  P. Piccini,et al.  Functional Neural Transplantation III , 2012 .

[140]  M. Politis,et al.  ISSN 1537-744X; doi:10.1100/2011/172893 Serotonergic Dysfunction in Parkinson’s Disease and Its Relevance to Disability , 2011 .

[141]  P. Piccini,et al.  Brain imaging after neural transplantation. , 2010, Progress in brain research.

[142]  Christer Halldin,et al.  The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain , 2008, Neuropsychopharmacology.

[143]  F. Verhey,et al.  Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data , 2005, Journal of Neural Transmission.

[144]  S. Kish.  Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? , 2003, Advances in neurology.

[145]  O. Isacson,et al.  Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells , 2003, Annals of neurology.

[146]  K. Jellinger,et al.  The pathology of Parkinson's disease. , 2001, Advances in neurology.

[147]  A. J. Stoessl,et al.  Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.

[148]  M. Glass,et al.  Cannabinoid receptors and their endogenous agonists. , 1998, Annual review of pharmacology and toxicology.

[149]  S. Goldman,et al.  Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients. , 1997, Stereotactic and functional neurosurgery.

[150]  E Bertrand,et al.  Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. , 1997, Folia neuropathologica.

[151]  S. G. Owen,et al.  Thyroid antibodies in myxoedema. , 1958, Lancet.

[152]  M. Politis.  C O M M E N T a R Y Open Access , 2022 .